Pagibaximab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePagibaximab
Drug Alias NamePagibaximabum帕昔单抗帕吉昔单抗帕戈巴昔单抗A-110 (Applied Molecular Evolution/Biosynexus) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionLipoteichoic acid inhibitors
TargetsLipoteichoic acid
Therapy Area/IndicationsSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApplied Molecular Evolution IncBiosynexus Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosynexus Incorporated
Active IndicationsN/A
Inactive IndicationsSepsis

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG